Navigation Links
Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
Date:9/10/2013

ted with ICS, as recommended in the guidelines, continue to experience symptoms that can impact their ability to lead a full life."

Despite current treatment options, at least 40 percent of patients with asthma remain symptomatic and may experience potentially life-threatening asthma exacerbations (attacks).

"We are committed to studying tiotropium across a wide range of asthma patients from mild to severe across all age groups, and we are encouraged by the results we have seen with tiotropium in asthma to date," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Results from the MezzoTinA-asthma® studies presented at ERS build on previous positive study results for tiotropium from the PrimoTinA-asthma® studies in patients with severe asthma. Collectively, these results show tiotropium, when approved, could become an important new option for asthma patients across a range of severities who remain symptomatic despite current standard treatments."

Key Results from the MezzoTinA-Asthma® Phase 3 Studies
The data are from a set of replicate Phase 3 studies; MezzoTinA-asthma® 1 and MezzoTinA-asthma® 2 are two paired international, double-blind, randomized, placebo- and active-controlled, parallel-group trials that involved asthma patients ages 18-75 years who remained symptomatic while on medium-dose ICS. A total of 2,103 patients were randomized to receive tiotropium 2.5 mcg or 5 mcg once daily delivered via the Respimat® inhaler, salmeterol 50 mcg twice daily (as the active comparator), or placebo, for 24 weeks. Pre-specified co-primary endpoints were peak forced expiratory volume (FEV1)(0-3h) response and trough FEV1 response after 24 weeks. ACQ responder rate was the third co-primary endpoint, performed on
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
4. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
5. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
6. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
7. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
8. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
9. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
10. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
11. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 31, 2011 Ambry Genetics today introduces their ...  The Ambry CancerArray™ is a high resolution exon-focused ... probe density coverage in over 400 known cancer-associated ... functionally important cancer regions. (Logo:   ...
... 31, 2011 CANTEL MEDICAL CORP. (NYSE: ... & CEO, will be presenting at the CL King 9th ... 11:15 AM EDT on Tuesday, September 13, 2011 at the ... Q & A session immediately following the presentation. In addition, ...
Cached Medicine Technology:Ambry Genetics Announces Launch of Their CancerArrayâ„¢ Product and Services Utilizing aCGH Technology 2
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... is widespread among U.S. adolescents and young adults ages 14 ... the University at Buffalos Research Institute on Addictions (RIA). ... the first national survey of its kind show problem gambling ... (for example, gambling more than you intended or stealing money ...
... Vascular Insights LLC announced,today that it has received ... (FDA) to market its ClariVein(TM) infusion catheter for,infusion ... ClariVein(TM) is a percutaneous, 2 2/3 Fr (0.035") ... that enhances fluid dispersion in the,treatment area., ...
... 6 Epitomics, Inc. announced,today that its Hangzhou ... and production of its novel line of rabbit ... standard for quality management and ultimately the finest ... Dr. Guo-Liang Yu,President and CEO of Epitomics, Inc., ...
... Care Management: Making a ... Difference Today and Tomorrow, HARRISBURG, ... Medical Officer, will deliver the clinical keynote,address on Wednesday afternoon, ... the World of Care Management. Dr. Petrulis will,present Care Management: ...
... at dilated veins seen with cirrohosis but aren,t sensitive ... New noninvasive methods to detect esophageal bleeding in people ... Italian and American researchers. , About 25 percent of ... are extremely dilated veins commonly seen with cirrhosis. Variceal ...
... bowel movement, serious complications can follow, experts note , , ... have identified a marker that might predict which pregnant ... is essentially a baby,s first bowel movement, excreted in ... It is considered a sign of fetal distress. A ...
Cached Medicine News:Health News:Estimated 750,000 problem gamblers among America's youth 2Health News:Estimated 750,000 problem gamblers among America's youth 3Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Noninvasive Procedures Show Promise for Esophageal Bleeding 2Health News:Doctors Discover Marker for Meconium Passage During Delivery 2
The most versatile 90 full field perimeter for static- and kinetic perimetry. It incorporates standard White-on-White and Blue-on-Yellow static perimetry. Octopus 101 covers all the needs in clinics ...
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... The Humphrey Matrix represents the ... Using frequency doubling technology, the Humphrey ... thorough visual field evaluation and assess ... enables you to provide complete long-term ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: